DWTX (Dogwood Therapeutics) Revenue: $0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DWTX Dogwood Therapeutics Inc DWTX
26 GF Score
Price $2.07
! 1 Warning Sign
View Full Analysis

What is Dogwood Therapeutics Revenue?

Dogwood Therapeutics DWTX -10.92% 26 Revenue is $0.00 Mil as of Jun. 2026. GuruFocus rates DWTX with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Dogwood Therapeutics's revenue for the three months ended in Jun. 2026 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00 Mil. Dogwood Therapeutics's Revenue per Share for the three months ended in Jun. 2026 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Dogwood Therapeutics  (NAS:DWTX) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Dogwood Therapeutics Revenue Related Terms

Dogwood Therapeutics Revenue Historical Data

* Premium members only.

The historical data trend for Dogwood Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dogwood Therapeutics Revenue Chart

Dogwood Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Dogwood Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DWTX vs RLYB, ALDX, ACRV: Revenue Comparison

For the Biotechnology subindustry, Dogwood Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dogwood Therapeutics Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dogwood Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where Dogwood Therapeutics's Revenue falls into.


DWTX
26GF Score
Dogwood Therapeutics Inc DWTX
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dogwood Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $0.00 Mil mean?
Dogwood Therapeutics (DWTX) has a Revenue of $0.00 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Dogwood Therapeutics and its competitors.
Is Dogwood Therapeutics' Revenue too high?
Dogwood Therapeutics' current Revenue is $0.00 Mil. Overall, Dogwood Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Dogwood Therapeutics' Revenue compare to RLYB and ALDX?
Dogwood Therapeutics' Revenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Dogwood Therapeutics and its competitors. Dogwood Therapeutics's current Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dogwood Therapeutics stock overvalued right now?
Dogwood Therapeutics (DWTX) has a current Revenue of $0.00 Mil. The current Revenue is $0.00 Mil. Dogwood Therapeutics' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Dogwood Therapeutics (DWTX), the current Revenue is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dogwood Therapeutics Business Description

Address 44 Milton Avenue, Alpharetta, GA, USA, 30009
Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.
26GF Score

Get the complete analysis for DWTX

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.07
Price